An advisory committee of the FDA voted to support the use of Aimmune Therapeutics’ (NASDAQ:AIMT) PALFORZIA in children and teens with peanut allergy. The committee voted seven-to-two that the efficacy data and eight-to...
Tag - Aimmune Therapeutics
